Research Online

Introduction: Fatty acid–binding protein 3 (FABP3) is a biomarker of neuronal membrane disruption, associated with lipid dyshomeostasis—a notable Alzheimer’s disease (AD) pathophysiological change. We assessed the association of cerebrospinal fluid

[1]  K. Blennow,et al.  Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study , 2022, Biomedicines.

[2]  K. Blennow,et al.  Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults , 2022, Neurobiology of Aging.

[3]  F. Jessen,et al.  Interrelations of Alzheimer´s disease candidate biomarkers neurogranin, fatty acid‐binding protein 3 and ferritin to neurodegeneration and neuroinflammation , 2020, Journal of neurochemistry.

[4]  A. Fonteh,et al.  Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies , 2020, Frontiers in Physiology.

[5]  K. Blennow,et al.  Interleukin 10 and Heart Fatty Acid-Binding Protein as Early Outcome Predictors in Patients With Traumatic Brain Injury , 2020, Frontiers in Neurology.

[6]  K. Blennow,et al.  Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults , 2020, Neurobiology of Aging.

[7]  Philip S. Insel,et al.  Determining clinically meaningful decline in preclinical Alzheimer disease , 2019, Neurology.

[8]  K. Blennow,et al.  Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis , 2019, Cellular and Molecular Life Sciences.

[9]  Kevin S. Hanson,et al.  Effect of age, ethnicity, sex, cognitive status and APOE genotype on amyloid load and the threshold for amyloid positivity , 2019, NeuroImage: Clinical.

[10]  Kathryn Goozee,et al.  A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease , 2019, Science Advances.

[11]  L. Parnetti,et al.  Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies , 2018, Future Neurology.

[12]  Yen-Wen Wu,et al.  The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease , 2018, Scientific Reports.

[13]  Joanne S. Robertson,et al.  The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults , 2018, Intelligence.

[14]  Yi Su,et al.  Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype , 2018, Brain : a journal of neurology.

[15]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[16]  P. Calabresi,et al.  Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia , 2017, Alzheimer's Research & Therapy.

[17]  C. Rowe,et al.  Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort , 2017, Alzheimer's & dementia.

[18]  K. Schaller,et al.  H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury , 2017, PloS one.

[19]  R. Martins,et al.  Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.

[20]  K. Blennow,et al.  Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration , 2017, Translational Psychiatry.

[21]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[22]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[23]  K. Blennow,et al.  Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years. , 2015, Journal of Alzheimer's disease : JAD.

[24]  C. Rowe,et al.  Comparison of MR-less PiB SUVR quantification methods , 2015, Neurobiology of Aging.

[25]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[26]  I. Kubota,et al.  Association of Heart-Type Fatty Acid-Binding Protein with Cardiovascular Risk Factors and All-Cause Mortality in the General Population: The Takahata Study , 2014, PloS one.

[27]  Pierrick Bourgeat,et al.  En Attendant Centiloid , 2014 .

[28]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[29]  O. Andreassen,et al.  Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration , 2013, Molecular Neurodegeneration.

[30]  R. Perneczky,et al.  Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[31]  Leslie M. Shaw,et al.  Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.

[32]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[33]  P. Calabresi,et al.  CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. , 2011, Journal of Alzheimer's Disease.

[34]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[35]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[36]  C. Rowe,et al.  The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.

[37]  K. Blennow,et al.  Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. , 2013, Journal of Alzheimer's disease : JAD.

[38]  R. Coleman,et al.  Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .